Medworxx Announces TELUS Health Will Offer Its Patient Flow Platform

  Medworxx Announces TELUS Health Will Offer Its Patient Flow Platform

        Medworxx will bring additional value to TELUS Health customers

Business Wire

TORONTO -- December 16, 2013

Medworxx Solutions Inc. ("Medworxx") (TSX VENTURE: MWX) today announced that
TELUS Health will now offer customers the Medworxx Patient Flow Platform,
enabling health care practitioners to better analyze and monitor patient
health in an acute care environment. Comprised of Medworxx Clinical Criteria,
Bed Management System, and Forms and Assessments, the platform is available as
part of TELUS Health’s suite of technology solutions.

“Medworxx is excited to collaborate with TELUS Health and continue to expand
Medworxx market penetration,” said Dan Matlow, President and CEO, Medworxx.
“We look forward to the opportunity this partnership brings in building
awareness and adoption of Medworxx technology in our key markets.”

Medworxx Patient Flow is a natural complement to Clinical Information Systems
(CIS) such as TELUS’ OACIS. TELUS Health’s OACIS streamlines data through a
single, intuitive source where clinicians can access, document and analyze a
patient’s profile to identify and address their most urgent needs, ultimately
increasing efficiency and productivity to deliver better healthcare.

“The addition of Medworxx to TELUS Health’s offering will bring additional
value to our customers through our synergistic technologies and provide TELUS
Health’s customers with additional capabilities to help drive proactive
decision-making at the point of care,” said Kasra Moozar, vice-president,
Healthcare Delivery Solutions, TELUS Health. “We are pleased to partner with
Medworxx to bring their solutions to our customers as part of our expanding
suite of acute care technology.”

About Medworxx
Medworxx delivers health information solutions to over 350 hospitals
internationally; including Canada, United States and United Kingdom. Medworxx
helps hospitals meet patient flow challenges, and requirements in compliance
and education. Medworxx Clinical Criteria – flagship of Medworxx Patient Flow
that includes electronic bed board and independent assessment components –
currently serves over 35% of the acute care beds in Canada. Founded in 2004,
Medworxx is based in Toronto, ON, and publicly traded on the TSX Venture
Exchange: MWX.


About TELUS Health
TELUS Health is the leading information and communication technology partner
to Canada’s health system. With a portfolio of telehomecare, electronic
medical and health records, consumer health, benefits management and pharmacy
management solutions, TELUS Health gives health authorities, providers,
physicians, patients and consumers the power to turn information into better
health outcomes. For more information about TELUS Health, please visit

TELUS (TSX: T, NYSE: TU) is a leading national telecommunications company in
Canada, with $11.3 billion of annual revenue and 13.3million customer
connections, including 7.8million wireless subscribers, 3.3million wireline
network access lines, 1.4million Internet subscribers and 776,000 TELUS TV
customers. Led since 2000 by President and CEO, Darren Entwistle, TELUS
provides a wide range of communications products and services, including
wireless, data, Internet protocol (IP), voice, television, entertainment and

In support of our philosophy to give where we live, TELUS, our team members
and retirees have contributed more than $300million to charitable and
not-for-profit organizations and volunteered 4.8million hours of service to
local communities since 2000. Fourteen TELUS Community Boards lead TELUS’
local philanthropic initiatives. TELUS was honoured to be named the most
outstanding philanthropic corporation globally for 2010 by the Association of
Fundraising Professionals, becoming the first Canadian company to receive this
prestigious international recognition.

For more information about TELUS, please visit

The statements made in this press release may contain forward-looking
statements that may involve a number of risks and uncertainties. Actual events
or results could differ materially from the company’s expectations and
projections. The TSX Venture Exchange has not reviewed this press release and
neither approved nor disapproved the information contained in this press


Susan Gershman
T: 1.800.321.1591 | T: 416.642.1278 x322
Dan Matlow
T: 1.800.321.1591 | T: 416.642.1278 x311
President & Chief Executive Officer
Press spacebar to pause and continue. Press esc to stop.